This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK antitrust watchdog's latest drug-pricing setback leaves plenty to chew on

By Simon Zekaria ( November 22, 2024, 16:08 GMT | Comment) -- A court setback for the UK competition regulator this week in its long-running case against Pfizer and Flynn Pharma over drug pricing is a lesson that how it goes about finding infringements can be as important as what infringements it finds. The Competition Appeal Tribunal remade the CMA's decision, and while the drugmakers' penalties ended up similar, the court picked large holes in its key pricing case. The CMA must think carefully before choosing to mount a challenge.The UK antitrust regulator has again been on the receiving end of criticism by competition judges in its sprawling drug pricing dispute against Pfizer and Flynn Pharma....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections